GHRL and hypertensive disorder: Despite the clear benefits of ghrelin as a therapy to ameliorate myocardial dysfunction and adverse cardiac remodeling in hypertension, as well as both acute and chronic heart failure, the two important limitations hindering it as a viable therapy are: that ghrelin peptide is currently expensive to produce clinical therapeutic doses and that it has a short half-life (9–13 min).